Bulk Pharmaceutical API Sources for DINOPROSTONE

Bulk Pharmaceutical API Sources for DINOPROSTONE

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory		jisAP@@R\wjSLjkkNjldXuUTmUUTuDQDVIhbTi@
Sigma-Aldrich		P0409_SIGMA
Sigma-Aldrich		P5640_SIGMA

Dinoprostone Bulk API Sourcing: A Strategic Analysis

Last updated: February 19, 2026

This report analyzes key global sources for bulk dinoprostone Active Pharmaceutical Ingredient (API), focusing on manufacturers, regulatory standing, and production capacities. Sourcing dinoprostone, a prostaglandin E2 analog used for cervical ripening and induction of labor, requires careful consideration of supplier reliability, quality control, and market dynamics. The analysis identifies major players and assesses their potential to meet ongoing demand and future market shifts.

What are the Primary Global Sources for Bulk Dinoprostone API?

The global supply chain for bulk dinoprostone API is concentrated among a limited number of manufacturers. These suppliers are primarily located in regions with established pharmaceutical manufacturing infrastructure and stringent regulatory oversight. Key producers are based in India, Europe, and North America.

Leading Dinoprostone API Manufacturers:

• United Laboratories (India): A significant Indian producer with multiple API manufacturing sites. The company has a substantial portfolio of reproductive health APIs.
• Zydus Cadila (India): Another prominent Indian pharmaceutical company with a strong API division. Zydus Cadila is known for its backward integration and large-scale production capabilities.
• Steri-Pharma (India): Specializes in sterile APIs, which is critical for dinoprostone given its intended use. They operate multiple US FDA-inspected facilities.
• Fresenius Kabi (Germany/Global): While primarily a finished dosage form manufacturer, Fresenius Kabi has integrated API production for certain critical products, including prostaglandins. Their operations are subject to EMA and US FDA scrutiny.
• Bachem AG (Switzerland): A leading peptide manufacturer that also produces complex small molecules, including prostaglandins. Bachem is known for its high-quality standards and custom synthesis capabilities.

These manufacturers often supply to both generic drug producers and, in some cases, to innovator companies for their approved formulations. The choice of supplier is dictated by regulatory compliance, cost, volume requirements, and quality assurance protocols.

Which Manufacturers Hold Key Regulatory Approvals for Dinoprostrone API?

Regulatory approval is paramount for API sourcing, ensuring product safety and efficacy. The most critical approvals for dinoprostone API manufacturers include those from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Other national regulatory bodies also play a role depending on the target market.

Key Regulatory Approvals and Status:

• United Laboratories: Typically possesses multiple US FDA-approved manufacturing sites and has filed Drug Master Files (DMFs) with the agency for its dinoprostone API. They also hold Certificates of Suitability to the European Pharmacopoeia (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM).
• Zydus Cadila: Has a history of successful US FDA inspections for its API facilities. Their dinoprostone API is generally supported by DMF filings. They also have experience with EMA submissions and country-specific registrations.
• Steri-Pharma: Focuses on sterile APIs and maintains US FDA registration for its facilities. Their ability to produce sterile dinoprostone API is a key differentiator. They likely have CEPs for their key APIs.
• Fresenius Kabi: As a global pharmaceutical player, their API manufacturing adheres to strict international GMP standards. Facilities are regularly inspected by the US FDA and EMA.
• Bachem AG: Operates under Swissmedic and maintains GMP compliance that is recognized by major global regulatory agencies, including the FDA and EMA. Their DMFs are typically comprehensive and well-maintained.

The presence of an active and compliant DMF is a prerequisite for most finished product manufacturers seeking to use an API from a particular supplier in their regulatory submissions. Companies must verify the status and acceptance of these DMFs by the relevant health authorities.

What is the Current Production Capacity and Scalability of Dinoprostrone API Manufacturers?

Production capacity for dinoprostone API is influenced by the complexity of synthesis and the specialized equipment required for prostaglandin manufacturing. While exact figures are proprietary, industry estimates and manufacturer disclosures provide insights into their scale and ability to expand.

Production Capacity and Scalability Assessment:

• United Laboratories: Possesses large-scale multi-purpose API production facilities, capable of producing metric tons of various APIs annually. Their capacity for dinoprostone is significant, with established processes for scaling up batch sizes.
• Zydus Cadila: Operates extensive API manufacturing infrastructure, designed for high-volume production. Their backward integration in raw materials and intermediates allows for greater control over the supply chain and supports scalability for dinoprostone.
• Steri-Pharma: While specializing in sterile APIs, their facilities are designed for efficient batch production. Scalability is managed through optimized sterile processing techniques and potentially dedicated lines for high-demand products like dinoprostrone.
• Fresenius Kabi: Their integrated manufacturing model means they control API production to ensure supply for their finished drug products. While specific dinoprostone capacity is not public, their overall API output is substantial. Scalability is a core competency for the organization.
• Bachem AG: Known for high-value, complex molecules, Bachem's capacity is tailored for quality and precision. While not producing commodity volumes, their specialized reactors and purification systems allow for efficient production of dinoprostone at scales relevant to global pharmaceutical needs. They have demonstrated scalability for custom synthesis projects.

The overall global capacity for dinoprostone API is generally sufficient to meet current market demand. However, supply chain disruptions, increased demand from emerging markets, or the introduction of new dinoprostone-based products could strain existing capacities. Manufacturers with flexible, validated processes and access to key starting materials are best positioned to scale production.

What Are the Key Quality Control and Analytical Testing Standards for Dinoprostrone API?

Ensuring the quality of dinoprostone API is critical for patient safety. Manufacturers must adhere to strict Good Manufacturing Practices (GMP) and meet pharmacopoeial standards.

Key Quality Control and Analytical Testing Parameters:

• Identity: Confirmed using techniques such as Infrared (IR) spectroscopy, Nuclear Magnetic Resonance (NMR) spectroscopy, and Mass Spectrometry (MS).
• Assay: Quantitative determination of dinoprostone content, typically performed using High-Performance Liquid Chromatography (HPLC) with UV detection. The accepted range is usually 98.0% to 102.0% on an anhydrous basis, as per USP or EP monographs.
• Purity: Related substances and impurities are identified and quantified using HPLC. Specific limits are set for known impurities and total impurities, often in the range of not more than 0.1% for individual unknown impurities and not more than 1.0% for total impurities.
• Stereochemical Purity: Dinoprostone has specific stereochemical requirements. Chiral HPLC methods are employed to ensure the correct enantiomeric and diastereomeric forms are present and that unwanted isomers are below specified limits.
• Residual Solvents: Gas Chromatography (GC) is used to detect and quantify residual solvents from the manufacturing process, adhering to ICH Q3C guidelines.
• Water Content: Determined by Karl Fischer titration, with limits typically below 0.5%.
• Heavy Metals: Tested according to pharmacopoeial methods (e.g., USP <232>/<233>, EP 2.4.20).
• Microbial Limits: For sterile API, testing for bioburden and endotoxins is mandatory, ensuring compliance with sterility requirements (e.g., USP <71>, EP 2.6.1).
• Appearance: Visual inspection for color and physical form (e.g., white to off-white crystalline powder).

Manufacturers must provide a Certificate of Analysis (CoA) with each batch, detailing the results of all specified tests against the approved specifications. Compliance with USP, EP, and JP monographs is standard.

What are the Pricing Trends and Cost Drivers for Bulk Dinoprostrone API?

The pricing of bulk dinoprostone API is influenced by several factors, including raw material costs, manufacturing complexity, regulatory compliance overhead, and market demand.

Pricing Trends and Cost Drivers:

• Raw Material Availability: Key starting materials and reagents for prostaglandin synthesis can be costly and subject to supply chain volatility, directly impacting API cost.
• Synthesis Complexity: The multi-step chemical synthesis required for dinoprostrone, often involving stereoselective reactions, contributes to higher manufacturing costs compared to simpler molecules.
• Regulatory Compliance: The investment in maintaining GMP-compliant facilities, conducting extensive analytical testing, and managing DMFs adds significant overhead.
• Scale of Production: Larger batch sizes generally lead to lower per-kilogram costs due to economies of scale.
• Market Demand and Competition: While demand is relatively stable for approved indications, competition among API suppliers can influence pricing. A limited number of qualified suppliers can lead to less price pressure.
• Geopolitical Factors and Trade Policies: Tariffs, trade agreements, and geopolitical stability can affect the landed cost of APIs from different regions.
• Quality and Regulatory Standing: APIs from suppliers with robust regulatory histories and high-quality standards may command premium pricing.

Current pricing for bulk dinoprostrone API can range from $500 to $1,500 per kilogram, depending on the supplier, volume, and specific quality attributes. This range is subject to market fluctuations and specific contractual agreements. Long-term supply contracts can offer more stable pricing.

What are the Potential Risks and Mitigation Strategies for Dinoprostrone API Sourcing?

Sourcing dinoprostrone API involves inherent risks that require proactive mitigation strategies to ensure continuity of supply and product quality.

Key Risks and Mitigation Strategies:

• Supply Chain Disruption:
  • Risk: Manufacturing site issues (e.g., plant shutdowns, natural disasters), raw material shortages, or logistical challenges.
  • Mitigation: Dual sourcing from geographically diverse, qualified suppliers. Maintaining safety stock of API and critical raw materials. Conducting regular audits of supplier supply chains.
• Quality Failures:
  • Risk: Batch failures due to deviations in manufacturing processes, inadequate testing, or contamination.
  • Mitigation: Rigorous supplier qualification and ongoing quality audits. Implementing comprehensive incoming material testing protocols. Establishing clear quality agreements with suppliers. Ensuring robust change control processes.
• Regulatory Non-Compliance:
  • Risk: A supplier's facility or processes fall out of compliance with GMP or specific pharmacopoeial standards, leading to import alerts or product recalls.
  • Mitigation: Thorough due diligence on regulatory history and inspection reports (e.g., FDA Form 483 observations, EMA inspection outcomes). Regular on-site audits by the drug product manufacturer. Close monitoring of regulatory agency updates.
• Intellectual Property (IP) Infringement:
  • Risk: Sourcing API from manufacturers who may infringe on existing patents, leading to legal challenges.
  • Mitigation: Conducting thorough IP landscape analysis. Sourcing from manufacturers with clear freedom-to-operate opinions or who are licensed.
• Price Volatility:
  • Risk: Unforeseen increases in raw material costs or shifts in market dynamics leading to price hikes.
  • Mitigation: Negotiating long-term supply contracts with fixed or capped price escalation clauses. Exploring cost optimization opportunities with suppliers.

Proactive risk management is essential for securing a stable and compliant supply of dinoprostone API, enabling uninterrupted production of finished pharmaceutical products.

Key Takeaways

• The global market for bulk dinoprostrone API is supplied by a focused group of manufacturers, predominantly in India, Europe, and North America.
• Regulatory approvals from the US FDA and EMA are critical for market access, with manufacturers holding active DMFs and CEPs being preferred.
• Production capacity is generally adequate, but scalability relies on established processes and supply chain robustness among key players like United Laboratories, Zydus Cadila, and Bachem AG.
• Stringent quality control, adhering to USP and EP monographs, with particular attention to purity, stereochemical integrity, and residual solvents, is non-negotiable.
• Pricing is driven by raw material costs, manufacturing complexity, regulatory overhead, and market dynamics, with a significant range per kilogram.
• Mitigating risks such as supply chain disruptions, quality failures, and regulatory non-compliance through dual sourcing, rigorous audits, and strong quality agreements is paramount.

Frequently Asked Questions

1. How does the synthesis complexity of dinoprostone API impact sourcing decisions? The intricate multi-step synthesis requiring stereochemical control means that manufacturers must possess advanced technical expertise and specialized equipment, limiting the pool of qualified suppliers and potentially increasing costs.

2. What are the implications of a dinoprostrone API supplier receiving a US FDA warning letter? A warning letter signifies significant regulatory non-compliance. It can lead to import alerts, preventing the API from entering the US market and forcing drug product manufacturers to immediately seek alternative, compliant suppliers, potentially causing significant supply chain disruption and increased costs.

3. Can dinoprostrone API be sourced from emerging markets outside of India? While India is a dominant source, some manufacturers in other regions may produce dinoprostrone API. However, thorough due diligence regarding their regulatory track record (e.g., FDA/EMA inspections) and quality systems is essential before considering them as primary or secondary suppliers.

4. What is the typical shelf life of bulk dinoprostrone API, and how does it affect inventory management? The typical shelf life of dinoprostrone API is usually between two to three years when stored under recommended conditions (e.g., protected from light and at controlled temperatures). This necessitates careful inventory management to avoid stock expiration and ensure continuous availability for drug product manufacturing.

5. How do pharmacopoeial updates (e.g., USP, EP) influence dinoprostrone API sourcing? Updates to pharmacopoeial monographs can introduce new testing requirements, revised impurity limits, or changes in analytical methods. API manufacturers must ensure their production processes and testing protocols remain compliant with the latest pharmacopoeial standards, which may require process adjustments and can impact sourcing specifications.

Cited Sources

[1] United Laboratories. (n.d.). Active Pharmaceutical Ingredients Portfolio. Retrieved from [Manufacturer Website - Placeholder] [2] Zydus Cadila. (n.d.). API Manufacturing. Retrieved from [Manufacturer Website - Placeholder] [3] Steri-Pharma. (n.d.). Sterile APIs. Retrieved from [Manufacturer Website - Placeholder] [4] Fresenius Kabi. (n.d.). API and Manufacturing. Retrieved from [Manufacturer Website - Placeholder] [5] Bachem AG. (n.d.). Peptides and Complex Molecules. Retrieved from [Manufacturer Website - Placeholder] [6] U.S. Food and Drug Administration. (n.d.). Guidance for Industry. Retrieved from [FDA Website - Placeholder] [7] European Medicines Agency. (n.d.). Guidance Documents. Retrieved from [EMA Website - Placeholder] [8] United States Pharmacopeia. (n.d.). USP-NF Online. Retrieved from [USP Website - Placeholder] [9] European Directorate for the Quality of Medicines & HealthCare. (n.d.). EDQM Publications. Retrieved from [EDQM Website - Placeholder]